Evidence map›Paper›PMID 40927311›Full record

ArticleJournal of immunotherapy and precision oncology2025

Exceptional Response to Immunotherapy-based Treatment in Compound

Ayushi Gianchandani, Darshana Desai, Janani Sambath, Darshana Patil, Prashant Kumar, Shambhavi Singh, Chetan Madre, Ruturaj Deshpande, Anjali Parab, Niyati Shah and 8 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunotherapy and precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ayushi GianchandaniImperial College London, London, United Kingdom.
Darshana DesaiDepartment of Medical Oncology, Sir H N Reliance Foundation Hospital and Research Centre, Mumbai, India.
Janani SambathManipal Academy of Higher Education (MAHE), Manipal, Karnataka, India.
Darshana PatilDatar Cancer Genetics, Nashik, Maharashtra, India.
Prashant KumarDatar Cancer Genetics, Nashik, Maharashtra, India.
Shambhavi SinghDepartment of Precision Oncology, Sir H N Reliance Foundation Hospital and Research Centre, Mumbai, India.
Chetan MadreDepartment of Medical Oncology, Sir H N Reliance Foundation Hospital and Research Centre, Mumbai, India.
Ruturaj DeshpandeDepartment of Medical Oncology, Sir H N Reliance Foundation Hospital and Research Centre, Mumbai, India.
Anjali ParabDepartment of Medical Oncology, Sir H N Reliance Foundation Hospital and Research Centre, Mumbai, India.
Niyati ShahDepartment of Medical Oncology, Sir H N Reliance Foundation Hospital and Research Centre, Mumbai, India.
Darshit ShahDepartment of Precision Oncology, Sir H N Reliance Foundation Hospital and Research Centre, Mumbai, India.
Pritam KatariaDepartment of Precision Oncology, Sir H N Reliance Foundation Hospital and Research Centre, Mumbai, India.
Shrikanth AtluriDepartment of Surgical Oncology, Sir H N Reliance Foundation Hospital and Research Centre, Mumbai, India.
Marzi MehtaDepartment of Surgical Oncology, Sir H N Reliance Foundation Hospital and Research Centre, Mumbai, India.
Aditya ShreenivasDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Centre, Duarte, CA, USA.
Rajan DatarDatar Cancer Genetics, Nashik, Maharashtra, India.
Razelle KurzrockCentre for Genomic Sciences and Precision Medicine, College of Wisconsin, Milwaukee, WI, USA.
Sewanti LimayeDepartment of Medical Oncology, Sir H N Reliance Foundation Hospital and Research Centre, Mumbai, India.ORCID https://orcid.org/0009-0003-4989-9117

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of non-small cell lung cancer (NSCLC) with limited treatment options and poor prognosis.

Indexed as

EGFR mutationimmunotherapypulmonary sarcomatoid carcinoma (PSC)

Identifiers

PMID40927311
PMCPMC12416483

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.